Understanding of ROS-Inducing Strategy in Anticancer Therapy
Top Cited Papers
Open Access
- 19 December 2019
- journal article
- review article
- Published by Hindawi Limited in Oxidative Medicine and Cellular Longevity
- Vol. 2019, 1-12
- https://doi.org/10.1155/2019/5381692
Abstract
Redox homeostasis is essential for the maintenance of diverse cellular processes. Cancer cells have higher levels of reactive oxygen species (ROS) than normal cells as a result of hypermetabolism, but the redox balance is maintained in cancer cells due to their marked antioxidant capacity. Recently, anticancer therapies that induce oxidative stress by increasing ROS and/or inhibiting antioxidant processes have received significant attention. The acceleration of accumulative ROS disrupts redox homeostasis and causes severe damage in cancer cells. In this review, we describe ROS-inducing cancer therapy and the anticancer mechanism employed by prooxidative agents. To understand the comprehensive biological response to certain prooxidative anticancer drugs such as 2-methoxyestradiol, buthionine sulfoximine, cisplatin, doxorubicin, imexon, and motexafin gadolinium, we propose and visualize the drug-gene, drug-cell process, and drug-disease interactions involved in oxidative stress induction and antioxidant process inhibition as well as specific side effects of these drugs using pathway analysis with a big data-based text-mining approach. Our review will be helpful to improve the therapeutic effects of anticancer drugs by providing information about biological changes that occur in response to prooxidants. For future directions, there is still a need for pharmacogenomic studies on prooxidative agents as well as the molecular mechanisms underlying the effects of the prooxidants and/or antioxidant-inhibitor agents for effective anticancer therapy through selective killing of cancer cells.Keywords
Funding Information
- Ministry of Environment (2017001970001, 2018001350006)
This publication has 119 references indexed in Scilit:
- Melatonin suppresses cisplatin-induced nephrotoxicity via activation of Nrf-2/HO-1 pathwayNutrition & Metabolism, 2013
- Risk of Heart Failure in Breast Cancer Patients After Anthracycline and Trastuzumab Treatment: A Retrospective Cohort StudyJNCI Journal of the National Cancer Institute, 2012
- Imexon Induces an Oxidative Endoplasmic Reticulum Stress Response in Pancreatic Cancer CellsMolecular Cancer Research, 2012
- Regulation of survival, proliferation, invasion, angiogenesis, and metastasis of tumor cells through modulation of inflammatory pathways by nutraceuticalsCancer and Metastasis Reviews, 2010
- Stereotactic Body Radiation Therapy for Inoperable Early Stage Lung CancerJAMA, 2010
- Increased levels of superoxide and H2O2 mediate the differential susceptibility of cancer cells versus normal cells to glucose deprivationBiochemical Journal, 2009
- Progress in Gynecologic Cancer Research: The Gynecologic Oncology Group ExperienceSeminars in Oncology, 2008
- Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2Carcinogenesis: Integrative Cancer Research, 2008
- NQO1-activated phenothiazinium redox cyclers for the targeted bioreductive induction of cancer cell apoptosisFree Radical Biology & Medicine, 2007
- Diversity of structures and properties among catalasesCellular and Molecular Life Sciences, 2004